These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34967625)

  • 1. Chemo-Enzymatic PEGylation/POxylation of Murine Interleukin-4.
    Haas D; Hauptstein N; Dirauf M; Driessen MD; Ruopp M; Schubert US; Lühmann T; Meinel L
    Bioconjug Chem; 2022 Jan; 33(1):97-104. PubMed ID: 34967625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Site-Specific POxylation of Interleukin-4.
    Lühmann T; Schmidt M; Leiske MN; Spieler V; Majdanski TC; Grube M; Hartlieb M; Nischang I; Schubert S; Schubert US; Meinel L
    ACS Biomater Sci Eng; 2017 Mar; 3(3):304-312. PubMed ID: 33465929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prolonged circulating lives of single-chain Fv proteins conjugated with polyethylene glycol: a comparison of conjugation chemistries and compounds.
    Lee LS; Conover C; Shi C; Whitlow M; Filpula D
    Bioconjug Chem; 1999; 10(6):973-81. PubMed ID: 10563766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Insights into Site-Specific Interferon-α2a Bioconjugates Originated from PEG, LPG, and PEtOx.
    Hauptstein N; Pouyan P; Kehrein J; Dirauf M; Driessen MD; Raschig M; Licha K; Gottschaldt M; Schubert US; Haag R; Meinel L; Sotriffer C; Lühmann T
    Biomacromolecules; 2021 Nov; 22(11):4521-4534. PubMed ID: 34643378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Linear Polyglycerol for N-terminal-selective Modification of Interleukin-4.
    Tully M; Hauptstein N; Licha K; Meinel L; Lühmann T; Haag R
    J Pharm Sci; 2022 Jun; 111(6):1642-1651. PubMed ID: 34728175
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemical and enzymatic site specific PEGylation of hGH.
    da Silva Freitas D; Mero A; Pasut G
    Bioconjug Chem; 2013 Mar; 24(3):456-63. PubMed ID: 23432141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. μPET imaging of the pharmacokinetic behavior of medium and high molar mass (89)Zr-labeled poly(2-ethyl-2-oxazoline) in comparison to poly(ethylene glycol).
    Wyffels L; Verbrugghen T; Monnery BD; Glassner M; Stroobants S; Hoogenboom R; Staelens S
    J Control Release; 2016 Aug; 235():63-71. PubMed ID: 27235979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-terminal mono-PEGylation of growth hormone antagonist: correlation of PEG size and pharmacodynamic behavior.
    Wu L; Ho SV; Wang W; Gao J; Zhang G; Su Z; Hu T
    Int J Pharm; 2013 Sep; 453(2):533-40. PubMed ID: 23796830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemical and Enzymatic Site Specific PEGylation of hGH: The Stability and in vivo Activity of PEG-N-Terminal-hGH and PEG-Gln141-hGH Conjugates.
    Grigoletto A; Mero A; Zanusso I; Schiavon O; Pasut G
    Macromol Biosci; 2016 Jan; 16(1):50-6. PubMed ID: 26350165
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioconjugation of a Fibroblast Activation Protein Targeted Interleukin-4.
    Ruopp M; Zhu S; Worschech R; Haas D; Maschauer S; Prante O; Meinel L; Lühmann T
    ACS Biomater Sci Eng; 2023 Oct; 9(10):5580-5588. PubMed ID: 37721169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Readily adaptable release kinetics of prodrugs using protease-dependent reversible PEGylation.
    Böttger R; Knappe D; Hoffmann R
    J Control Release; 2016 May; 230():88-94. PubMed ID: 27067364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Site-Specific Albumination as an Alternative to PEGylation for the Enhanced Serum Half-Life in Vivo.
    Yang B; Lim SI; Kim JC; Tae G; Kwon I
    Biomacromolecules; 2016 May; 17(5):1811-7. PubMed ID: 27050863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modulation of the anti-inflammatory effects of phosphatidylserine-containing liposomes by PEGylation.
    Quan H; Park HC; Kim Y; Yang HC
    J Biomed Mater Res A; 2017 May; 105(5):1479-1486. PubMed ID: 27998010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymer selection impacts the pharmaceutical profile of site-specifically conjugated Interferon-α2a.
    Hauptstein N; Pouyan P; Wittwer K; Cinar G; Scherf-Clavel O; Raschig M; Licha K; Lühmann T; Nischang I; Schubert US; Pfaller CK; Haag R; Meinel L
    J Control Release; 2022 Aug; 348():881-892. PubMed ID: 35764249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of PEGylation and immune complex formation on the pharmacokinetics and biodistribution of recombinant interleukin 10 in mice.
    Alvarez HM; So OY; Hsieh S; Shinsky-Bjorde N; Ma H; Song Y; Pang Y; Marian M; Escandón E
    Drug Metab Dispos; 2012 Feb; 40(2):360-73. PubMed ID: 22083830
    [TBL] [Abstract][Full Text] [Related]  

  • 16. C-terminal mini-PEGylation of a marine peptide N6 had potent antibacterial and anti-inflammatory properties against Escherichia coli and Salmonella strains in vitro and in vivo.
    Li T; Yang N; Teng D; Mao R; Hao Y; Wang X; Wang J
    BMC Microbiol; 2022 May; 22(1):128. PubMed ID: 35549900
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.
    Stefan N; Zimmermann M; Simon M; Zangemeister-Wittke U; Plückthun A
    Bioconjug Chem; 2014 Dec; 25(12):2144-56. PubMed ID: 25350699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-function engineering of interferon-beta-1b for improving stability, solubility, potency, immunogenicity, and pharmacokinetic properties by site-selective mono-PEGylation.
    Basu A; Yang K; Wang M; Liu S; Chintala R; Palm T; Zhao H; Peng P; Wu D; Zhang Z; Hua J; Hsieh MC; Zhou J; Petti G; Li X; Janjua A; Mendez M; Liu J; Longley C; Zhang Z; Mehlig M; Borowski V; Viswanathan M; Filpula D
    Bioconjug Chem; 2006; 17(3):618-30. PubMed ID: 16704199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Site-specific PEGylation of HR2 peptides: effects of PEG conjugation position and chain length on HIV-1 membrane fusion inhibition and proteolytic degradation.
    Danial M; van Dulmen TH; Aleksandrowicz J; Pötgens AJ; Klok HA
    Bioconjug Chem; 2012 Aug; 23(8):1648-60. PubMed ID: 22770564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyethylene glycol modified FGF21 engineered to maximize potency and minimize vacuole formation.
    Xu J; Bussiere J; Yie J; Sickmier A; An P; Belouski E; Stanislaus S; Walker KW
    Bioconjug Chem; 2013 Jun; 24(6):915-25. PubMed ID: 23594041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.